Trials / Completed
CompletedNCT04124601
Neoadjuvant Chemoradiotherapy With Sequential Ipilimumab and Nivolumab in Rectal Cancer
Neoadjuvant CHemoradiotherapy With Sequential Ipilimumab and NivOlumab in RECtal Cancer (CHINOREC): a Prospective Randomized, Open-label, Multicenter, Phase II Clinical Trial
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 80 (actual)
- Sponsor
- Johannes Laengle, MD, PhD · Academic / Other
- Sex
- All
- Age
- 18 Years – 100 Years
- Healthy volunteers
- Not accepted
Summary
This prospective randomized, open-label, multicenter, phase II clinical trial investigates the safety and tolerability of standard neoadjuvant chemoradiotherapy (CRT) with sequential ipilimumab and nivolumab in rectal cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| RADIATION | Chemoradiotherapy | Capecitabine tablet with fractionated radiotherapy |
| DRUG | Ipilimumab | Infusion |
| DRUG | Nivolumab | Infusion |
Timeline
- Start date
- 2020-06-01
- Primary completion
- 2024-03-15
- Completion
- 2024-03-15
- First posted
- 2019-10-11
- Last updated
- 2024-04-23
Locations
5 sites across 1 country: Austria
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04124601. Inclusion in this directory is not an endorsement.